Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Axcend and Microsaic Systems Enter a Worldwide Integration and Joint Marketing and Sales Agreement


PROVO, Utah and WOKING, England, Feb. 27, 2020 /PRNewswire/ -- Axcend® today announced it has signed a worldwide Integration and Joint Marketing and Sales Agreement with Microsaic Systems (AIM:MSYS).

The primary logo for Axcend, a provider of innovative, compact nanoflow high-performance liquid chromatographs (HPLCs) that deliver dramatic improvements in portability, ease of operation, rapid and convenient deployment, and coupling to other analytical systems (such as mass spectrometry). As a result, Axcend allows scientists to take HPLC Anywhere (TM). For more information, visit www.AxcendCorp.com or call 801-405-9545. (PRNewsfoto/Axcend)

Under terms of the agreement, Axcend and Microsaic will work closely to integrate their respective scientific instruments into tightly coupled, compact, easy-to-use and cost-competitive liquid chromatography/mass spectrometry solutions. Combination LC/MS systems are highly valued by scientists and chemists around the world. Through this agreement, Axcend and Microsaic will work jointly and separately to market and sell their integrated LC/MS solutions globally.

"We have an award-winning, lightweight yet powerful HPLC that is easy-to-use and cost-competitive, especially on an operational basis," said Glen Mella, CEO and Co-Founder of Axcend. "Yet many scientists need the added benefit of an LC/MS system to produce greater analytical insights. We're confident that Microsaic will be an excellent partner for delivering compelling solutions to our customers."

Axcend's and Microsaic's Products

The Axcend Focus LC® utilizes 150mm internal diameter capillary columns and single or dual UV-absorption detectors in compact, easily swappable cartridges to deliver reliable and fast HPLC detection and analytical outcomes. The Axcend Focus LC requires dramatically less solvent (under 10mL per week of continuous use) and produces significantly less waste, generating huge cost-savings versus traditional HPLC systems. Additionally, its small footprint and the ability to operate it in wireless, battery-powered environments allow it to be used nearly anywhere; from on a laboratory bench to inside a glove box, as well as in the field.

Microsaic has developed powerful, chip-based, benchtop and point-of-need mass spectrometry instruments that are designed to deliver processing and manufacturing agility, as well as commercial productivity, to the pharmaceutical and biopharmaceutical industries. Its core product ? the 4500 MiD®? is a robust and compact MS systems that retains the functionality of larger conventional mass spectrometry instruments but is easier to use by non-specialists, consumes significantly less energy and has lower running costs.

"We are particularly excited by this partnership which not only combines incredibly compact products in one very powerful system, but also leverages our shared resources for marketing, sales and distribution channels on a global basis," said Glenn Tracey, Microsaic CEO. "As far as I am aware, there is no other solution which combines such an incredible LC/MS offering into one small footprint today."

About Axcend

Axcend is a provider of innovative, hand-portable and high-performance liquid chromatography (HPLC) systems. These solutions allow scientists to deliver HPLC Anywhere® and provide dramatic improvements in portability, ease-of-operation, and rapid and convenient deployment, as well as coupling to other analytical systems.

About Microsaic Systems

Microsaic Systems plc (AIM:MSYS) is working with a range of established global life science OEM partners, distributors and research organizations to co-develop and commercialize new mass spectrometry solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision-making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors. For more information, please go to www.microsaic.com.  

Axcend, the Axcend logo, Axcend Focus LC, and HPLC Anywhere are trademarks of Axcend, LLC. Microsaic and 4500 MiD are trademarks of Microsaic Systems plc. All other trademarks are property of their respective owners.

AXCEND CONTACT:


David Politis, 801-556-8184, David.Politis@AxcendCorp.com




MICROSAIC CONTACTS:


Glenn Tracey, CEO (Microsaic Systems plc)

+44 (0) 1483 751 577

Bevan Metcalf, FD




N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)


Tom Salvesen (Corporate Broking)




IFC Advisory Ltd (Financial PR)

+44 (0) 20 3934 6630

Graham Herring


Florence Chandler


 

SOURCE Axcend


These press releases may also interest you

at 07:10
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent...

at 07:10
IMV Inc. , a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company's business and clinical operations amid...

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....

at 07:05
Generation Bio and Vir Biotechnology today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's current or future human monoclonal...



News published on 27 february 2020 at 10:05 and distributed by: